Use of Pulsed Low-Dose Rate Radiotherapy in Refractory Malignancies

Jing Yan, Ju Yang, Yang Yang, Wei Ren, Juan Liu, Shanbao Gao, Shuangshuang Li, Weiwei Kong, Lijing Zhu, Mi Yang, Xiaoping Qian, Baorui Liu, Jing Yan, Ju Yang, Yang Yang, Wei Ren, Juan Liu, Shanbao Gao, Shuangshuang Li, Weiwei Kong, Lijing Zhu, Mi Yang, Xiaoping Qian, Baorui Liu

Abstract

Background: Most tumor cell lines exhibited low-dose hyperradiosensitivity (LDHRS) to radiation doses lower than 0.3 Gy. Pulsed low-dose rate radiotherapy (PLDR) took advantage of LDHRS and maximized the tumor control process. In this study, we retrospectively analyzed patients receiving PLDR for refractory malignancies.

Patients and methods: In total, 22 patients were included in our study: 9 females and 13 males. The median age was 61 years old. All the patients previously received multiline treatments and failed with an estimated survival less than 6 months. Thus, palliative PLDR was given. The PLDR was delivered using 10 fractions of 2 Gy/day, with an interval of 3 minutes, for 5 days per week. The dose rate was 6.67 cGy/min. The median follow-up was 1 year (range 8-30 months). Nine patients underwent PLDR for reirradiation due to locally recurrent diseases. The time interval from last irradiation was 11 to 168 months. Ten patients received PLDR due to poor performance status. Three patients were given PLDR for bulky tumor. The irradiated sites included primary disease (seven patients), locally recurrent disease (nine patients), and retroperitoneal adenopathy (six patients).

Results: Five patients developed grade 3 or 4 toxicities. No grade 5 toxicities occurred. All the toxicities recovered after treatments. In general, the 1-year local-regional control rate was approximately 40%, and almost all the patients developed progression at the second year after PLDR. The 6-month survival rate was 76%, and the 1-year survival rate was 69%. For the three patients given PLDR for bulky tumor, all of them achieved partial remission 1 month after the PLDR, and one patient achieved complete response at the fourth month.

Conclusion: PLDR is an effective and safe option not only for reirradiation but also for patients with poor performance status or bulky tumors. A prospective clinical trial (NCT03061162) is ongoing to validate our results.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Flowchart of the recruitment process.
Figure 2
Figure 2
(A) Kaplan-Meier analysis of local regional-free survival. (B) Kaplan-Meier analysis of overall survival.
Figure 3
Figure 3
(A) Delineation of the bulky disease. (B) Evaluation of treatment response by computed tomography.

References

    1. Morris DE. Clinical experience with retreatment for palliation. Semin Radiat Oncol. 2000;10:210–221.
    1. Lee DY, Chunta JL, Park SS. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2013;86:978–985.
    1. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506.
    1. Park SS, Chunta JL, Robertson JM. MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation. Int J Radiat Oncol Biol Phys. 2011;80:885–892.
    1. Zhang P, Wang B, Chen X. Local tumor control and normal tissue toxicity of pulsed low-dose rate radiotherapy for recurrent lung cancer: an in vivo animal study. Dose Response. 2015;13
    1. Wobb J, Krueger SA, Kane JL. The effects of pulsed radiation therapy on tumor oxygenation in 2 murine models of head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;92:820–828.
    1. Meyer K, Krueger SA, Kane JL. Pulsed radiation therapy with concurrent cisplatin results in superior tumor growth delay in a head and neck squamous cell carcinoma murine model. Int J Radiat Oncol Biol Phys. 2016;96:161–169.
    1. Cannon GM, Tome WA, Robins HI, Howard SP. Pulsed reduced dose-rate radiotherapy: case report: a novel re-treatment strategy in the management of recurrent glioblastoma multiforme. J Neurooncol. 2007;83:307–311.
    1. Richards GM, Tome WA, Robins HI. Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region. Breast Cancer Res Treat. 2009;114:307–313.
    1. Adkison JB, Tome W, Seo S. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:835–841.
    1. Pierquin B, Calitchi E, Mazeron JJ. A comparison between low dose rate radiotherapy and conventionally fractionated irradiation in moderately extensive cancers of the oropharynx. Int J Radiat Oncol Biol Phys. 1985;11:431–439.
    1. Tome WA, Howard SP. On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. Br J Radiol. 2007;80:32–37.
    1. Dilworth JT, Krueger SA, Dabjan M. Pulsed low-dose irradiation of orthotopic glioblastoma multiforme (GBM) in a pre-clinical model: effects on vascularization and tumor control. Radiother Oncol. 2013;108:149–154.
    1. Li GH, Zhu B, Yang F. Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck. Exp Ther Med. 2012;3:869–872.
    1. Marples B. Is low-dose hyper-radiosensitivity a measure of G2-phase cell radiosensitivity? Cancer Metastasis Rev. 2004;23:197–207.
    1. Joiner MC, Marples B, Lambin P. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 2001;49:379–389.
    1. Marples B, Lambin P, Skov KA, Joiner MC. Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol. 1997;71:721–735.
    1. Lin PS, Wu A. Not all 2 Gray radiation prescriptions are equivalent: cytotoxic effect depends on delivery sequences of partial fractionated doses. Int J Radiat Oncol Biol Phys. 2005;63:536–544.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren